Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...

Mycobacterial cell wall–DNA complex (MCC) is an effective treatment modality for bladder cancer, and has a favorable safety profile when compared with intravesical therapy using live bacillus ...

Morales’s protocol of 6-weekly intravesical instillations of bacillus Calmette–Guerin (BCG), introduced in 1976, has survived to this date. BCG is superior to chemotherapy as an adjuvant agent ...

While multiple trials were launched to investigate the use of alternative therapies such as intravesical chemotherapy, ...

First-line intravesical BCG therapy had failed for all the patients, who were then recommended for radical cystectomy by their treating physicians. Notably, said Douglas M. Dahl, MD, of ...

Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis live, attenuated culture preparation; 50mg per vial; pwd for intravesical administration after reconstitution and dilution ...

BCG-Unresponsive patients achieved a 100% CR rate at six months; no severe treatment-related adverse events reported. The trial is assessing intravesical TARA-002, the company’s investigational ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

(Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high ...